Omeprazole Sulfide CAS 73590-85-9 Purity >99.0% (HPLC) Factory

Omeprazole Sulfide (CAS: 73590-85-9) is an intermediate used in the production of the gastric proton pump inhibitors, Omeprazole (CAS: 73590-58-6) and Esomeprazole (CAS: 119141-88-7), Esomeprazole Sodium (CAS: 161796-78-7). As a degradation product, it is reported to be a direct-acting inhibitor of cytochrome P450 2C19 in pooled human liver microsomes (IC50 = 9.7 μM). Omeprazole Sulfide is a metabolite of Omeprazole. Esomeprazole Sodium is the sodium salt form of esomeprazole. It is a commonly used anti-ulcer drug, which was first successfully developed by the Swedish company Astra Zeneca first. It belongs to a proton pump inhibitor. The proton pump inhibitor is the primary choice for treating peptic ulcer, gastro-oesophageal reflux disease and other acid-related diseases. Currently commonly clinically used PPI include five kinds: Omeprazole, Lansoprazole, Rabeprazole, Pantoprazole and Esomeprazole. As the first PPI, the omeprazole’s drug efficacy in treating acid-related diseases has been widely recognized. Esomeprazole is the S-isomer of Omeprazole, which can reduce gastric acid secretion by specific targeting mechanism. It is the specific inhibitor for the proton pump inhibitor in the parietal cell.  Owing to the metabolic advantage of esomeprazole, it has a higher bioavailability and more consistent pharmacokinetics than its counterpart, Omeprazole Sodium, increasing the drug that reaches the proton pump.  Its role of gastric acid control is much better than other proton pumps inhibitors such as Lansoprazole, Pantoprazole, and Rabeprazole.